Biotech controls


The biotechnology industry in Britain should be regulated and its clinical trials scrutinised by independent scientists, says the House of Commons science and technology committee in a report this week. The report follows an inquiry into British Biotech, Europe’s largest biotech company. Earlier this year its share price dropped by more than two-thirds after allegations by its former head of clinical trials, Andrew Millar, that poor results were being suppressed (This Week, 4 July, p 20). “What he did and said was in the public interest,” says Alan Williams,
  • 首页
  • 游艇租赁
  • 电话
  • 关于我们